Kindeva Drug Delivery expands UK facility to commercialise green propellant

Published: 6-Jun-2024

The UK expansion of Kindeva's capabilities will allow the company to expedite the commercialisation of its low-GWP propellant, as well as offering a space for the analytical laboratory services team

Drug-device combination product CDMO Kindeva Drug Delivery has expanded its Loughborough, UK facilities at the Charnwood Campus Science Innovation and Technology Park.

This initiative aims to support the commercialisation of its green propellant for inhaled drug products, as well as offering a dedicated space for Kindeva’s analytical laboratory services team — who will be positioned here once renovations are completed later this year. 

The move doubles Kindeva’s UK laboratory footprint, and will relocate around 50 quality control employees from the company’s Loughborough manufacturing site. 

Further site expansions planned for the future

The company has also announced its investment into a second manufacturing line at the Loughborough site.

It will produce pressurised metered-dose inhaler (pMDI) products, which will be powered by propellants with a low global warming potential (GWP). 

This expansion also offers the potential for future development and sustainability initiatives. 

Carl Brookes, Vice President, Manufacturing and Operations – Loughborough at Kindeva, commented: “This is an exciting time for green propellants, and as Kindeva continues to develop more sustainable technologies and processes, we will continue to evaluate the potential across all our drug device platforms and our sites. Our expansion on Charnwood Campus will help Kindeva to provide the necessary tools our employees need to succeed.”

You may also like